Bio-Path Holdings Says Phase 2 Clinical Trial Of Prexigebersen In Combination With Low Dose Cytarabine (LDAC) For Acute Myeloid Leukemia (AML) Showed Combination Was "Well-Tolerated" And Showed "Early Anti-Leukemic Activity" In 50% Of Evaluable Patients